###begin article-title 0
Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer
###end article-title 0
###begin p 1
Conceived and designed the experiments: EAM RS. Performed the experiments: CMS CKI LRA LC JS. Analyzed the data: EAM CMS SL CKI MCA MP LC MGG CJO GM AJB. Wrote the paper: EAM RS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Estrogen is a pivotal regulator of cell proliferation in the normal breast and breast cancer. Endocrine therapies targeting the estrogen receptor are effective in breast cancer, but their success is limited by intrinsic and acquired resistance.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 1558 1566 <span type="species:ncbi:9606">patients</span>
###xml 1632 1640 <span type="species:ncbi:9606">patients</span>
With the goal of gaining mechanistic insights into estrogen action and endocrine resistance, we classified estrogen-regulated genes by function, and determined the relationship between functionally-related genesets and the response to tamoxifen in breast cancer patients. Estrogen-responsive genes were identified by transcript profiling of MCF-7 breast cancer cells. Pathway analysis based on functional annotation of these estrogen-regulated genes identified gene signatures with known or predicted roles in cell cycle control, cell growth (i.e. ribosome biogenesis and protein synthesis), cell death/survival signaling and transcriptional regulation. Since inducible expression of c-Myc in antiestrogen-arrested cells can recapitulate many of the effects of estrogen on molecular endpoints related to cell cycle progression, the estrogen-regulated genes that were also targets of c-Myc were identified using cells inducibly expressing c-Myc. Selected genes classified as estrogen and c-Myc targets displayed similar levels of regulation by estrogen and c-Myc and were not estrogen-regulated in the presence of siMyc. Genes regulated by c-Myc accounted for 50% of all acutely estrogen-regulated genes but comprised 85% (110/129 genes) in the cell growth signature. siRNA-mediated inhibition of c-Myc induction impaired estrogen regulation of ribosome biogenesis and protein synthesis, consistent with the prediction that estrogen regulates cell growth principally via c-Myc. The 'cell cycle', 'cell growth' and 'cell death' gene signatures each identified patients with an attenuated response in a cohort of 246 tamoxifen-treated patients. In multivariate analysis the cell death signature was predictive independent of the cell cycle and cell growth signatures.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 54 62 <span type="species:ncbi:9606">patients</span>
These functionally-based gene signatures can stratify patients treated with tamoxifen into groups with differing outcome, and potentially identify distinct mechanisms of tamoxifen resistance.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 247 250 247 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Dellapasqua1">[1]</xref>
###xml 252 255 252 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-StrasserWeippl1">[2]</xref>
###xml 437 440 437 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Dellapasqua1">[1]</xref>
###xml 441 444 441 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Jordan1">[5]</xref>
###xml 571 574 571 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Smith1">[6]</xref>
###xml 1013 1016 1013 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Ali1">[7]</xref>
###xml 1017 1020 1017 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Nicholson1">[9]</xref>
###xml 1447 1463 1447 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Loi1">[reviewed in 10]</xref>
###xml 1616 1620 1616 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Loi2">[11]</xref>
###xml 431 436 <span type="species:ncbi:9606">women</span>
###xml 835 843 <span type="species:ncbi:9606">patients</span>
###xml 1052 1060 <span type="species:ncbi:9606">patients</span>
Among several advances that have contributed to the decreased mortality from breast cancer observed in the past decade, the routine use of adjuvant endocrine therapies directed at the estrogen-estrogen receptor (ER) pathway is a major contributor [1], [2]. Tamoxifen, which blocks estrogen action at its receptor, increases survival following a diagnosis of breast cancer and prevents the development of breast cancer in high risk women [1]-[5]. The more recently-developed aromatase inhibitors, which block estrogen synthesis, appear to be even more effective therapies [6]. Thus, targeting the estrogen receptor pathway is a validated, effective, biologically-based therapy for breast cancer. However, the overall success of this therapeutic approach is limited by both intrinsic and acquired resistance. A significant proportion of patients with ER-positive tumors do not have sustained objective responses, and many who do initially respond subsequently relapse due to the acquisition of endocrine resistance [7]-[9]. Prospective identification of patients who are not good candidates for adjuvant endocrine therapy would substantially facilitate clinical decision-making. To address this need, several gene expression signatures that cosegregate with poor outcome in tamoxifen-treated breast cancer have been derived using gene expression profiling, prospectively-selected candidate genes or differentially-expressed estrogen-regulated genes [reviewed in 10]. A gene expression grade index (GGI) developed as a molecular correlate of histological grade also cosegregates with poor response to tamoxifen therapy [11]. There is little overlap between the genes contained within these signatures, other than the frequent inclusion of genes involved in cell proliferation, and thus although potentially clinically useful, they offer limited insight into the molecular basis of endocrine resistance.
###end p 9
###begin p 10
###xml 588 591 588 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Ali1">[7]</xref>
###xml 592 595 592 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Nicholson1">[9]</xref>
###xml 1002 1023 1002 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Butt1">[reviewed in Ref. 12]</xref>
###xml 1110 1114 1110 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall1">[13]</xref>
###xml 1199 1207 1199 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1215 1236 1215 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Butt1">[reviewed in Ref. 12]</xref>
The biochemical and molecular basis of antiestrogen (tamoxifen) resistance has been the subject of intense investigation. Aberrations in ER expression and function, alterations in coactivator and corepressor expression, ligand-independent activation of ER via growth factor-mediated phosphorylation events, a switch from estrogen-driven cell-proliferation to EGFR/erbB2-driven proliferation and the overexpression of various signaling molecules, particularly the mitogen-activated protein kinases and various isoforms of protein kinase C, have all been implicated in endocrine resistance [7]-[9]. Consistent with the idea that deregulation of estrogen target genes, particularly those that mediate cell proliferation and survival, is another potential mechanism of endocrine resistance, overexpression of the estrogen-targeted cell cycle regulatory molecules c-Myc and cyclin D1, which occurs at high frequency in the clinical setting, has been associated with altered sensitivity to endocrine therapy [reviewed in Ref. 12]. Inducible expression of these genes can over-ride antiestrogen-induced growth arrest [13] and overexpression can modulate sensitivity to clinically-relevant antiestrogens in in vitro models [reviewed in Ref. 12].
###end p 10
###begin p 11
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Sorlie1">[14]</xref>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
Since estrogen is a multifunctional hormone, we reasoned that the approach of seeking to identify a minimal gene set associated with adverse outcome in tamoxifen-treated patients and the binary nature of many of the resulting classifications might obscure some of the complexity of the underlying biology. Furthermore, several of the endocrine response signatures have been derived using hierarchical clustering, which may not consistently result in stable classification in independent sample sets [14]. With the goal of gaining further mechanistic insights into estrogen action and therefore into endocrine resistance, we sought to classify estrogen-regulated genes by function, and then determine the impact of deregulation of distinct functionally-related sets of genes on the response to tamoxifen in breast cancer patients.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Gene expression profiling and identification of estrogen-regulated genes that are also c-Myc-regulated
###end title 13
###begin p 14
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall1">[13]</xref>
###xml 636 637 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 748 757 745 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g001">Fig. 1A&amp;B</xref>
###xml 861 862 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 887 894 884 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g001">Fig. 1D</xref>
###xml 1031 1032 1028 1029 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1074 1080 1071 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g001">Fig. 1</xref>
###xml 1130 1131 1127 1128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1220 1227 1217 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g001">Fig. 1D</xref>
###xml 1293 1297 1290 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall1">[13]</xref>
Since inducible expression of c-Myc can overcome the inhibitory effects of antiestrogens and recapitulate many of the effects of estrogen on molecular endpoints related to cell cycle progression [13] we reasoned that determining which estrogen-regulated genes were also targets of c-Myc might provide insights into the role of c-Myc in different aspects of estrogen action and in antiestrogen resistance. To this end, a series of clonal MCF-7 cell lines was developed that inducibly express c-Myc or c-Zip (a deletion mutant of c-Myc that lacks the N-terminal transactivation domains). Representative clones that had 17beta-estradiol (E2) and antiestrogen responses matched to those of the parental MCF-7 cells were chosen for further experiments (Fig. 1A&B). Zinc treatment resulted in increased c-Myc or c-Zip expression within 3 h, similar to the timing of E2 induction of c-Myc (see Fig. 1D). Induction of c-Myc led to re-initiation of cell cycle progression and regulation of molecular endpoints that mimicked the effects of E2, but induction of c-Zip was ineffective (Fig. 1). Cyclin D1 induction preceded S phase entry in E2-treated cells, but was not apparent in zinc-treated control or c-Myc transfected cells (Fig. 1D), consistent with previous data obtained using this model system [13].
###end p 14
###begin title 15
Effects of estrogen treatment and induction of c-Myc and c-Zip in antiestrogen-arrested cells.
###end title 15
###begin p 16
###xml 297 298 290 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 630 631 619 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 741 742 728 729 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 843 844 830 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 912 913 897 898 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cell lines stably transfected with the inducible vector pDeltaMT containing c-Myc, a c-Myc mutant lacking the entire N-terminal domain (c-Zip) or empty vector (Empty vector) were growth arrested with 10 nM ICI 182780 for 48 h. Cells were treated at time zero with either 100 nM 17beta-estradiol (E2) or vehicle (ethanol, EtOH) for the parental MCF-7, and 65 microM zinc for empty vector, c-Myc and c-Zip. (A, B) Cells additionally treated with nocodazole to prevent cell division of estrogen-stimulated cells were harvested for analysis of cell cycle phase distribution by flow cytometry. A: Representative histograms 36 h after E2 and nocodazole treatment; B: mean+/-SD of 3 independent experiments. Control (EtOH): open bars; Zn (red) or E2 (blue). (C) The proportion of cells in S phase was determined by flow cytometry at intervals after E2 or Zn treatment. Data are mean+/-SD of 3 independent experiments. E2, * filled circles; c-Myc, blacksquare, square, filled filled squares; c-Zip, black triangle filled triangles; EtOH, o open circles; Empty vector, square open squares. (D) Cell lysates were analysed by immunoblotting for the proteins shown. Arrowhead indicates a non-specific protein (NS).
###end p 16
###begin p 17
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Musgrove1">[15]</xref>
###xml 557 558 557 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 844 845 844 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 907 908 907 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 993 994 993 994 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1005 1012 1005 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g002">Fig. 2A</xref>
###xml 1014 1022 1014 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s001">Table S1</xref>
Using mitotically-selected cells, we previously established that MCF-7 cell cycle progression is antiestrogen-sensitive in early-to-mid G1 phase, but becomes independent of estrogen signaling 3-4 h before S phase entry [15]. We therefore selected a timepoint within the window of estrogen-dependent cell cycle progression, 6 h after estrogen treatment, and compared the gene expression profile generated after estrogen treatment with that following zinc induction of c-Myc or c-Zip. Initially, genes that were significantly up- or down-regulated following E2 treatment compared with vehicle-treated cells were identified (n = 799 genes, represented by 939 probesets, adjusted p<0.01 i.e. false discovery rate 1%). The estrogen-regulated genes were then divided into those that were regulated in the same direction following c-Myc induction or E2 treatment but not regulated by c-Zip induction, designated 'E2 and Myc' (adjusted p<0.01, 402/799 genes i.e. 50%), and the remainder, designated 'E2 not Myc' (Fig. 2A, Table S1).
###end p 17
###begin title 18
Comparison of genes regulated by estrogen and c-Myc.
###end title 18
###begin p 19
###xml 40 46 40 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g001">Fig. 1</xref>
###xml 113 114 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 462 463 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 561 562 557 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 583 584 579 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 926 927 922 923 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 946 947 942 943 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 206 211 <span type="species:ncbi:9606">Human</span>
The experimental design is described in Fig. 1, except that a concentration of 75 microM Zn was used. After 6 h E2 or Zn treatment, cells were harvested and transcript profiling undertaken using Affymetrix Human Genome U133 Plus 2.0 oligonucleotide microarrays. After normalisation and correction for multiple hypothesis testing, probesets that were significantly regulated in the same direction by estrogen or c-Myc (but not by c-Zip) were identified (adjusted P<0.01). (A) The number of up-regulated (filled) or down-regulated (hatched) genes classified as 'E2 and Myc' (red) or 'E2 not Myc' (blue) is shown. (B, C) The fold change in the expression of significantly-regulated probesets following estrogen treatment (relative to vehicle (EtOH) treatment) is shown compared with that following zinc induction of c-Myc (relative to zinc treatment of empty vector cells) as the average of three independent experiments. Red: 'E2 and Myc'; Blue: 'E2 not Myc'. (D) The overlap between probesets in the indicated categories and publically available databases of estrogen-regulated genes (open bars) and c-Myc-regulated genes (filled bars) is shown.
###end p 19
###begin p 20
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 122 129 122 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g002">Fig. 2B</xref>
###xml 146 147 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 240 241 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 426 427 426 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 508 509 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 702 703 702 703 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 778 779 778 779 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 799 806 799 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g002">Fig. 2C</xref>
###xml 848 852 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Tang1">[16]</xref>
###xml 871 875 871 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Zeller1">[17]</xref>
###xml 1068 1069 1068 1069 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1162 1169 1162 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g002">Fig. 2D</xref>
###xml 1216 1217 1216 1217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1235 1236 1235 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1246 1248 1246 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 1323 1324 1323 1324 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1418 1425 1418 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g002">Fig. 2D</xref>
###xml 1461 1462 1461 1462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1482 1483 1482 1483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1493 1496 1493 1496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;12</sup>
###xml 1545 1554 1545 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide</italic>
###xml 1675 1676 1675 1676 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1840 1845 1840 1845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 1893 1894 1893 1894 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2031 2035 2031 2035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall1">[13]</xref>
###xml 2046 2053 2046 2053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g001">Fig. 1D</xref>
The relationship between the response to E2 treatment or c-Myc induction for the 635 E2-upregulated probesets is shown in Fig. 2B. Those in the 'E2 and Myc' category formed a cluster which was largely distinct from the cluster designated 'E2 not Myc'. At the zinc concentration used for the microarray experiment, c-Myc expression after zinc induction was higher than after estrogen treatment, and consequently genes in the 'E2 and Myc' category were more strongly regulated by c-Myc than by estrogen. The 'E2 not Myc' cluster included the most highly-regulated probes and had an average relative expression of 0.97 after c-Myc induction. In contrast, the distribution of downregulated probes in the 'E2 not Myc' category essentially overlapped with that of the probes in the 'E2 and Myc' category (Fig. 2C). Databases of estrogen-responsive genes [16] and c-Myc targets [17] were used to give an indication of the proportion of the genes in each category that had been previously identified as either estrogen- or c-Myc-regulated. Almost 40% of the probes from the 'E2 not Myc' category that increased in expression were previously-documented estrogen targets (Fig. 2D), significantly more than the corresponding 'E2 and Myc' probes (P = 9.86x10-7, Fisher's exact test). A similarly high proportion of the probes in the 'E2 and Myc' category that increased in expression were present in the Myc target gene database (Fig. 2D), significantly more than in the 'E2 not Myc' category (P = 1.64x10-12), suggesting that this analysis identified many bona fide c-Myc targets that have not been previously described as estrogen targets. The presence of known c-Myc targets in the 'E2 not Myc' categories might result, in part, from misclassification, but likely also reflects cell-type specificity in the response to c-Myc induction. For example, CCND1 (cyclin D1), which is among the genes in the 'E2 not Myc' category, is present in the c-Myc target gene database but does not increase after c-Myc induction in this experimental model ([13], see also Fig. 1D).
###end p 20
###begin p 21
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 426 433 426 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g003">Fig. 3A</xref>
###xml 493 494 493 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 557 590 557 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSU79274, HSPC 111, DKC1, MKI67IP</italic>
###xml 607 613 607 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 645 654 645 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/Cip1</sup>
###xml 697 698 697 698 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 737 746 737 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g002">Fig. 2B&#8211;F</xref>
###xml 934 935 934 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1184 1193 1172 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g004">Fig. 4A&amp;B</xref>
###xml 1270 1271 1258 1259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1298 1321 1286 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSU79274, DKC1, MKI67IP</italic>
###xml 1363 1364 1351 1352 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1376 1385 1364 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g004">Fig. 4C&#8211;E</xref>
###xml 1421 1422 1409 1410 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1442 1447 1430 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GREB1</italic>
###xml 1452 1457 1440 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 1516 1517 1504 1505 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1562 1571 1550 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g004">Fig. 4F&amp;G</xref>
###xml 1596 1601 1584 1589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 1683 1691 1671 1679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSPC 111</italic>
###xml 1857 1865 1845 1853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSPC 111</italic>
###xml 1875 1879 1863 1867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Butt2">[18]</xref>
###xml 1970 1976 1958 1964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 1988 1992 1976 1980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Mukherjee1">[19]</xref>
###xml 2055 2056 2043 2044 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2204 2205 2192 2193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2241 2242 2229 2230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2277 2278 2265 2266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 886 891 <span type="species:ncbi:9606">human</span>
If a c-Myc-dependent pathway is an integral part of the response to estrogen, the changes in expression of targets in the 'E2 and Myc' category after estrogen treatment or zinc induction would be expected to be of similar magnitude, provided similar levels of c-Myc were achieved. To test this prediction, we adjusted the concentration of zinc so that the induction of c-Myc mRNA was similar to that after estrogen treatment (Fig. 3A), and examined the expression of selected genes from the 'E2 and Myc' category. The 5 genes examined all either increased (HSU79274, HSPC 111, DKC1, MKI67IP), or decreased (CDKN1A, encoding the CDK inhibitor p21WAF1/Cip1) in expression to a similar degree after E2 treatment or zinc induction of c-Myc (Fig. 2B-F). As a further test of the conclusion that these genes are estrogen regulated via an estrogen-mediated increase in c-Myc expression, MCF-7 human breast cancer cells were stimulated with E2 in the presence of siRNAs directed at c-Myc (siMyc). The most effective of the siRNAs tested, siMyc-17, reduced the estrogen induction of c-Myc protein and mRNA at 6-9 h from approximately5-fold to a statistically non-significant level of <2-fold (Fig. 4A&B and data not shown). In the presence of siMyc, none of the genes from the 'E2 and Myc' category tested (HSU79274, DKC1, MKI67IP), displayed significant induction after E2 treatment (Fig. 4C-E). In contrast two genes from the 'E2 not Myc' category, GREB1 and CCND1 (encoding cyclin D1), were both significantly induced by E2 in either the presence or absence of siMyc (Fig. 4F&G), despite evidence that CCND1 is a Myc target in other systems. More detailed examination of the regulation of HSPC 111 showed that its induction by estrogen required ongoing protein synthesis, did not occur in the presence of siMyc, and was accompanied by recruitment of c-Myc to the HSPC 111 promoter [18]. In addition, others have shown that c-Myc is required for estrogen-mediated decreases in CDKN1A expression [19]. Thus, estrogen regulation of all of these 5 genes from the 'E2 and Myc' category is dependent on c-Myc. Together these data provide strong evidence that our analysis reliably distinguished genes regulated by 'E2 and Myc' from those regulated by 'E2 not Myc', and that genes in the 'E2 and Myc ' category are regulated via estrogen induction of c-Myc.
###end p 21
###begin title 22
Estrogen and c-Myc regulation of selected genes.
###end title 22
###begin p 23
###xml 40 46 40 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g001">Fig. 1</xref>
###xml 185 186 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 233 237 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Butt2">[18]</xref>
The experimental design is described in Fig. 1. For the indicated genes, mRNA levels were quantitated by qRT-PCR and are presented as the mean+/-range or SEM of 2-3 experiments. EtOH, E2, Empty and c-Myc data in (C) are redrawn from [18].
###end p 23
###begin title 24
Effect of RNAi-mediated knockdown of c-Myc on regulation of selected genes after estrogen treatment.
###end title 24
###begin p 25
###xml 191 192 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 279 280 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cells were mock-transfected or transfected with 50 nM of control (non-targetting siRNA, siNT2) or Myc siRNA (siMYC17), treated with antiestrogen (ICI 182780) for 48 h, and then treated with E2 for 6 h (A) or 9 h (B-G). (A) Protein lysates were immunoblotted for c-Myc 6 h after E2 treatment and quantitated by densitometry. Data are the mean+/-range or SEM of 2-3 experiments. (B-G) For the indicated genes, mRNA levels were quantitated by qRT-PCR and are presented as the mean+/-SEM of 3 experiments.
###end p 25
###begin title 26
Pathway analysis of estrogen- and c-Myc-regulated genes
###end title 26
###begin p 27
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Draghici1">[20]</xref>
###xml 369 370 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 386 387 386 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 561 568 561 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t001">Table 1</xref>
###xml 1009 1016 1009 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g005">Fig. 5A</xref>
###xml 1018 1026 1018 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s002">Table S2</xref>
###xml 1057 1058 1057 1058 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1465 1472 1465 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g005">Fig. 5B</xref>
###xml 1474 1482 1474 1482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s002">Table S2</xref>
###xml 1654 1661 1654 1661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g005">Fig. 5C</xref>
###xml 1663 1671 1663 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s002">Table S2</xref>
In order to develop hypotheses about the biological processes regulated by estrogen in this system we undertook further analysis using the gene ontology tool Onto-Express [20] and Ingenuity Pathways Analysis, which uses a curated database of known functional interactions to identify networks of mammalian genes. The entire set of estrogen-regulated genes, i.e. both 'E2 and Myc' and 'E2 not Myc', contained a significant over-representation of genes in gene ontology biological process categories related to ribosome biogenesis, the cell cycle and cell death (Table 1). Ingenuity analysis of this geneset identified 4 networks with high scores for relevance to the input dataset. These had the following functional annotations: cancer, cell cycle, DNA replication, gene expression and cell death. One network consisted of genes with roles in the cell cycle and its gene signature was expanded by including estrogen-regulated genes from gene ontology categories related to the cell cycle and DNA replication (Fig. 5A, Table S2). Ingenuity analysis of the 'E2 not Myc' signature identified one high-scoring network that contained genes with roles in cell death and substantially overlapped with two of the high-scoring networks identified using the entire set of estrogen-regulated genes. The main clusters of the latter networks were therefore combined, and the resulting signature expanded by addition of genes from gene ontology categories related to cell death (Fig. 5B, Table S2). The fourth Ingenuity network derived from the entire estrogen-regulated geneset, consisting of genes with roles in transcriptional regulation, was not further modified (Fig. 5C, Table S2).
###end p 27
###begin title 28
Networks of estrogen-regulated genes.
###end title 28
###begin p 29
###xml 242 243 242 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 262 263 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
Gene ontology, Ingenuity Pathways analysis and HiMAP were used as detailed in the text to generate networks of estrogen-regulated genes identified by transcript profiling after 6 h estrogen treatment of antiestrogen-arrested cells. Yellow: 'E2 not Myc'; blue: 'E2 and Myc'. Some genes were included for the purposes of illustration e.g. ESR1, encoding the ER, and are not coloured. A: cell cycle; B: cell death; C: transcriptional regulation; D: cell growth.
###end p 29
###begin title 30
Gene ontology of all estrogen-regulated genes.
###end title 30
###begin p 31
The analysis used Onto-Express, with a binomial distribution model and false discovery rate (FDR) correction for multiple comparisons. Only categories with 3 or more genes are presented, and categories with related functions have been grouped together.
###end p 31
###begin p 32
###xml 86 94 86 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s003">Table S3</xref>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 324 329 324 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNE2</italic>
###xml 377 384 377 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A,</italic>
###xml 406 415 406 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Waf1/Cip1</sup>
###xml 819 827 819 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s003">Table S3</xref>
###xml 1076 1080 1076 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 1083 1090 1083 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g005">Fig. 5C</xref>
###xml 1276 1284 1276 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s003">Table S3</xref>
The functional annotation of the final gene signatures was confirmed using Ingenuity (Table S3). The annotation of the 'cell cycle' signature revealed a highly significant overrepresentation of genes involved in: DNA replication and DNA metabolism, e.g. several MCMs, PCNA, RFC2 and RFC4; cell cycle control, e.g. CCND1 and CCNE2, encoding cyclins D1 and E2, respectively, and CDKN1A, the gene encoding p21Waf1/Cip1, which forms a central node in this network; and cancer, including breast cancer. The 'cell death' signature was annotated as containing genes involved in cell death, apoptosis and survival. Cancer was also over-represented in this network. Interestingly, for this signature the functional annotations within cancer included invasion and migration as well as cell death and general oncogenic processes (Table S3), and cell movement was significantly overrepresented overall. The 'transcriptional regulation' signature included a number of nuclear receptor coregulators, and many of the genes have documented functional interactions with the estrogen receptor (ESR1) (Fig. 5C). The annotation of this network identified transcription and cancer as significantly over-represented, as was development of the mammary alveolus, albeit with a small number of genes (Table S3).
###end p 32
###begin p 33
###xml 385 392 385 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t001">Table 1</xref>
###xml 1061 1065 1061 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Rhodes1">[21]</xref>
###xml 1314 1318 1314 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Andersen1">[22]</xref>
###xml 1320 1324 1320 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Hinsby1">[23]</xref>
###xml 1511 1518 1511 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g005">Fig. 5D</xref>
###xml 1740 1744 1740 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Hinsby1">[23]</xref>
###xml 1982 1991 1982 1991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s002">Tables S2</xref>
###xml 1994 1996 1994 1996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s003">S3</xref>
###xml 740 745 <span type="species:ncbi:9606">Human</span>
###xml 840 845 <span type="species:ncbi:9606">human</span>
###xml 918 923 <span type="species:ncbi:4932">yeast</span>
###xml 962 967 <span type="species:ncbi:9606">human</span>
###xml 1706 1711 <span type="species:ncbi:9606">human</span>
The gene ontology classifications of estrogen-regulated genes and the processes represented by the Ingenuity networks displayed many overlapping categories. However, several processes linked by their importance in cell growth, i.e. the increase in cell mass that accompanies progress through the cell cycle, were amongst those most significantly over-represented in the gene ontology (Table 1) but were not well-represented in the Ingenuity networks, i.e. rRNA processing, ribosome biogenesis and protein biosynthesis. This was likely because much of the current understanding of these processes is based on studies in model systems other than mammalian cells. We therefore extended our analysis by predicting likely interactions using the Human Interactome Map (HiMAP), which builds networks based on known protein-protein interactions in human cells and on predictions from interactions in model organisms including yeast, co-ordinate expression in a panel of human tissue samples, shared biological function and conserved protein-protein interaction domains [21]. A gene signature for 'cell growth' was compiled from an initial small subnetwork identified by Ingenuity, together with genes that were in relevant gene ontology categories or encoded proteins that proteomic analysis has assigned to the nucleolus [22], [23], and estrogen-regulated genes that were predicted by HiMAP to have direct connections to these genes. The network generated by HiMAP from this list of genes was redrawn using Ingenuity (Fig. 5D) and contained three major clusters that were largely composed of predicted, rather than known, interactions. Using the gene ontology classifications, data from proteomic analysis of the human ribosome biogenesis pathway [23] and annotation of the final network using Ingenuity, these clusters were identified as genes involved in protein synthesis or RNA post-transcriptional modification, particularly splicing, and components of the 90S pre-ribosomal complex (Tables S2 & S3), consistent with the HiMAP prediction of functionally relevant interactions between these genes.
###end p 33
###begin p 34
###xml 204 210 204 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g005">Fig. 5</xref>
###xml 212 220 212 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002987.s002">Table S2</xref>
###xml 574 575 574 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 825 826 825 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 951 952 951 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 961 964 961 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;16</sup>
To gain potential insights into the role of c-Myc in estrogen-responsive biological processes, we determined what fraction of the genes in each signature was regulated by c-Myc in our experimental model (Fig. 5, Table S2). In total the 'cell cycle' gene signature contained 60 genes, of which 27 (45%) were regulated by both estrogen and c-Myc. Similarly, of the 'transcriptional regulation' signature 12 of 31 genes (39%) were regulated by c-Myc. The proportion of genes in these two networks regulated by estrogen and c-Myc was comparable with the 50% overall proportion (P = 0.42 and 0.20, respectively, Fisher's exact test). However, genes regulated by both estrogen and c-Myc comprised only one-third of the total genes in the 'cell death' network (19/55, i.e. 35%), significantly different from the overall proportion (P = 0.017). Conversely, the 'cell growth' gene signature contained significantly more genes regulated by c-Myc (102/123, 83%, P = 5.5x10-16). These data suggest that the degree to which estrogen regulation of cell cycle, cell growth and cell death is secondary to the induction of c-Myc varies significantly.
###end p 34
###begin title 35
Role of c-Myc induction in estrogen stimulation of cell cycle progression and cell growth
###end title 35
###begin p 36
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-White1">[24]</xref>
###xml 618 625 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g006">Fig. 6A</xref>
###xml 722 729 722 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g006">Fig. 6B</xref>
###xml 780 782 780 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 859 866 859 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g006">Fig. 6C</xref>
###xml 978 979 978 979 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1074 1081 1074 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g006">Fig. 6D</xref>
###xml 1092 1098 1092 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g004">Fig. 4</xref>
###xml 1223 1230 1223 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g006">Fig. 6E</xref>
###xml 935 940 <span type="species:ncbi:9606">human</span>
Cell growth is necessary but not sufficient for S phase entry and the two processes are closely co-ordinated [24]. Our pathway analysis indicated that estrogen may regulate cell growth principally via c-Myc. To test this prediction, we examined whether estrogen regulated cell growth in this model system. The first rate-limiting step in ribosome biogenesis is transcription of the 45S rRNA precursor, which is subsequently processed to yield rRNAs that are integral to the ribosomal subunits. The 5' externally transcribed spacer (5'ETS) of the 45S rRNA began to increase in abundance 6-8 h after estrogen treatment (Fig. 6A), significantly preceding the initiation of DNA synthesis, which was first apparent after 12 h (Fig. 6B). Similarly, total protein synthesis measured by [35S]-methionine incorporation was increased by 6-9 h after estrogen treatment (Fig. 6C). These endpoints were then measured in antiestrogen-arrested MCF-7 human breast cancer cells stimulated with E2 in the presence ofsiMyc-17, which reduced the induction of c-Myc protein to less than 2-fold (Fig. 6D, see also Fig. 4). Under these conditions, the increase in 5'ETS levels was inhibited, as was estrogen induction of total protein synthesis (Fig. 6E). Thus, estrogen activates ribosome biogenesis and protein synthesis in a c-Myc-dependent manner, as predicted by our pathway analysis.
###end p 36
###begin title 37
Effect of RNAi-mediated knockdown of c-Myc on cell growth after estrogen treatment.
###end title 37
###begin p 38
###xml 103 104 103 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 340 341 338 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 598 600 596 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 658 659 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 913 914 909 910 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1041 1043 1037 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
A, B: MCF-7 cells were growth arrested with 10 nM ICI 182780 for 48 h then treated with either 100 nM E2 or vehicle (ethanol) (A) Abundance of the 5'ETS of the 45S rRNA transcript was measured using qRT-PCR. Vehicle control, o open circles; estrogen, * filled circles. Data are mean+/-SEM of triplicate experiments. (B) Cells treated with E2 for the indicated times were additionally treated with BrdU 2 h before harvesting. BrdU content (immunofluorescence) and DNA content (propidium iodide staining) were measured using 2 parameter flow cytometry. (C) Overall protein synthesis was measured by [35S]-methionine incorporation at the indicated times after E2 treatment. Data are mean+/-range or SEM of 2-3 experiments. D, E: Cells were mock-transfected or transfected with 100 nM of control (RISC-free, RF,) or Myc siRNAs (siMYC17), treated with antiestrogen (ICI 182780) for 48 h, and then treated with 100 nM E2 or vehicle (ethanol). (D) Protein lysates were immunoblotted for c-Myc. (E) 5'ETS abundance (qRT-PCR) and protein synthesis ([35S]-methionine incorporation) were measured in the presence of control (RF) and c-Myc siRNAs (siMyc17) in duplicate experiments.
###end p 38
###begin title 39
Relationship between functional signatures and response to endocrine therapy
###end title 39
###begin p 40
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Loi2">[11]</xref>
###xml 457 461 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Bair1">[25]</xref>
###xml 646 653 646 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t002">Table 2</xref>
###xml 655 662 655 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g007">Fig. 7A</xref>
###xml 825 830 825 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 835 846 835 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NCOA1/SRC-1</italic>
###xml 849 852 849 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 898 899 898 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1270 1289 1270 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t003">Table 3, models 1&#8211;3</xref>
###xml 1343 1344 1343 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1395 1396 1395 1396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1449 1450 1449 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2108 2109 2108 2109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2130 2131 2130 2131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2152 2153 2152 2153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 229 236 <span type="species:ncbi:9606">patient</span>
###xml 306 311 <span type="species:ncbi:9606">women</span>
###xml 1162 1169 <span type="species:ncbi:9606">patient</span>
To determine whether the individual processes regulated by estrogen might have different impacts on the response to endocrine therapy, we examined the relationship between the estrogen-regulated gene signatures and breast cancer patient outcome using transcript profiles generated from a population of 246 women with ER-positive breast cancer who received tamoxifen as their only adjuvant systemic therapy [11]. A semi-supervised principal component method [25] was used to assess the ability of each signature to predict time to development of distant metastasis. The 'cell cycle', 'cell death' and 'cell growth' signatures were all prognostic (Table 2, Fig. 7A), but the 'transcriptional regulation' signature was not, although it contained some genes that were individually significant predictors of outcome (for example, CCND1 and NCOA1/SRC-1). MYC was not prognostic as a continuous variable (P = 0.372), and its inclusion in either the cell cycle or cell growth signatures did not influence their predictive ability. The three signatures that were significant remained predictive in multivariate models against standard clinicopathological parameters i.e. patient age, tumor grade, tumor size and lymph node status, whether analysed using the interquartile range (Table 3, models 1-3) or when treated as continuous variables (Cell cycle P = 0.001, HR 1.016, 95% CI 1.007-1.025; cell death P = 0.0001, HR 1.022, 95% CI 1.011-1.033; cell growth P = 0.002, HR 1.015, 95% CI 1.005-1.024). Since the 'cell cycle' and 'cell growth' signatures were strongly correlated with tumor grade, grade was omitted from the models for these signatures. To determine if the gene signatures gave prognostic information additional to the clinical variables described above, we generated a predictor based on a principal components analysis using the clinical variables, and then developed additional models using both the clinical variables and the individual gene signatures. Using this alternative approach, each signature still added significantly to the risk prediction using the clinical covariates alone (Cell cycle P = 0.002; cell death P = 0.05; cell growth P = 0.04).
###end p 40
###begin title 41
Relationship between estrogen-regulated gene signatures and response to tamoxifen therapy.
###end title 41
###begin p 42
###xml 252 258 252 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g005">Fig. 5</xref>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">Patients</span>
Kaplan-Meier survival curves of the relationship between time to distant metastasis and the indicated gene signatures, dichotomised at the 50th percentile, in a cohort of 246 breast cancer patients treated with tamoxifen. (A) Signatures illustrated in Fig. 5. (B) Subsets of the 'cell growth' signature. (C) Subsets of the 'cell death' signature. (D) Patients were sequentially stratified using the 'cell death' and 'cell cycle' signatures.
###end p 42
###begin title 43
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Analysis of functional signatures in tamoxifen-treated patients.
###end title 43
###begin p 44
The log-rank p was generated after 500 permutations.
###end p 44
###begin title 45
Cox regression analysis.
###end title 45
###begin p 46
For each signature the interquartile HR is shown i.e. highest vs. lowest quartile. Grade is treated as a continuous variable (1 vs. 2 vs. 3) while tumor size (</=2 cm vs. >2 cm), age (</=50 vs. >50 yrs), and nodal status (negative vs. positive) are binary variables.
###end p 46
###begin p 47
###xml 315 322 315 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t002">Table 2</xref>
###xml 324 331 324 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g007">Fig. 7B</xref>
###xml 671 678 671 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t002">Table 2</xref>
###xml 680 687 680 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g007">Fig. 7C</xref>
###xml 840 847 840 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t002">Table 2</xref>
###xml 849 856 849 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g007">Fig. 7C</xref>
To gain possible insights into the contribution of components of the processes represented by each signature, we further divided the signatures. When the 'cell growth' signature was subdivided into components representing RNA processing, ribosome biogenesis and protein synthesis, each was individually prognostic (Table 2, Fig. 7B). Because the 'cell death' signature contained some genes that also had roles in processes that might be expected to affect metastasis, i.e. cell migration and invasion, we assessed the prognostic ability of genes with a 'cell movement' annotation compared with the remainder of the signature. The 'cell movement' subgroup was predictive (Table 2, Fig. 7C). However, although for the remainder of the 'cell death' signature the high risk and low risk groups diverged, this was not statistically significant (Table 2, Fig. 7C).
###end p 47
###begin p 48
###xml 985 992 985 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002987-g007">Fig. 7D</xref>
###xml 1223 1239 1223 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t003">Table 3, Model 4</xref>
###xml 1281 1282 1281 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1333 1334 1333 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1386 1387 1386 1387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1614 1633 1614 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002987-t003">Table 3, Models 5&amp;6</xref>
###xml 1743 1744 1743 1744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1795 1796 1795 1796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1875 1876 1875 1876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1928 1929 1928 1929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
###xml 733 741 <span type="species:ncbi:9606">patients</span>
The question of whether these signatures identified distinct groups of patients is important in relation to both their potential clinical utility and a better understanding of the underlying biological mechanisms. There were strong correlations between the cell cycle and cell growth signatures (r = 0.653, p<0.01), but weaker associations between cell cycle and cell death (r = 0.326, p<0.01), or cell growth and cell death (r = 0.385, p<0.01). Consistent with the idea that the cell death signature might identify a distinct subset of patients, the discordance between classification on the basis of the cell cycle or cell death signatures was 42%, compared with 27% between the cell cycle and cell growth signatures. Furthermore, patients classified as low risk based on the 'cell death' signature, but not those classified as high risk on this basis, could be separated into groups of differing outcome on the basis of the 'cell cycle' signature (p = 0.015 and 0.67, respectively; Fig. 7D). Finally, multivariate analysis comparing all three signatures as continuous variables revealed that the cell death signature was predictive independent of the other two signatures whether analysed using the interquartile range (Table 3, Model 4), or as continuous variables (Cell cycle P = 0.058, HR 1.010, 95% CI 1.000-1.021; cell death P = 0.009, HR 1.013, 95% CI 1.003-1.023; cell growth P = 0.287, HR 1.006, 95% CI 0.995-1.017). In models including either 'cell cycle' or 'cell growth' against 'cell death' and the clinicopathological variables, all remained predictive when analysed using the interquartile range (Table 3, Models 5&6), although 'cell growth' did not when treated as a continuous variable (Cell death vs cell cycle: cell cycle P = 0.006, HR 1.013, 95% CI 1.004-1.023; cell death P = 0.038, HR 1.010, 95% CI 1.001-1.020. Cell death vs. cell growth: cell death P = 0.005, HR 1.014, 95% CI 1.004-1.024; cell growth P = 0.081, HR 1.009, 95% CI 0.999-1.019). The 'cell death' and 'cell cycle' signatures therefore apparently confer independent prognostic information.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 184 189 <span type="species:ncbi:9606">human</span>
Estrogen action is necessary both for the normal development of the female reproductive organs, including the mammary gland, and for the development and proliferation of a majority of human breast cancers. However, understanding the mechanisms underlying the physiological effects of this important hormone and how their deregulation impacts on sensitivity to therapies directed at the ER remains a significant challenge.
###end p 50
###begin title 51
Role of c-Myc in estrogen action
###end title 51
###begin p 52
###xml 455 459 455 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Adhikary1">[26]</xref>
###xml 593 597 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Cheng1">[27]</xref>
###xml 858 859 854 855 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 945 946 941 942 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 963 964 959 960 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 327 332 <span type="species:ncbi:9606">human</span>
By analysis based on functional annotation of acutely estrogen-regulated genes we have identified gene signatures that encompass four different aspects of estrogen action, and contain different proportions of c-Myc-responsive genes: cell cycle control, cell growth, cell death and transcriptional regulation. The proportion of human protein-coding genes that is c-Myc-responsive is estimated at 10-15% and many non-coding RNAs are also regulated by c-Myc [26]. In addition, c-Myc and ERalpha binding sites co-localise near the transcription start site of a subset of estrogen-responsive genes [27]. Nonetheless, the observation that as many as half of estrogen-responsive genes are also c-Myc-responsive is striking and unexpected, and argues strongly for a critical role for c-Myc in estrogen action. This was revealed by our focus on the acute effects of E2 and use of an experimental model designed to maximise sensitivity to the ability of E2 to promote the G1-S phase transition, in contrast with previous analyses which have often been undertaken over longer timeframes or in experimental models with less sensitivity to effects on proliferation. The different contributions of c-Myc-responsive genes to the different estrogen-responsive signatures indicates that the role of c-Myc may be specific to some processes, rather than global.
###end p 52
###begin p 53
###xml 318 322 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-DominguezSola1">[28]</xref>
###xml 433 437 433 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-DominguezSola1">[28]</xref>
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Leroy1">[29]</xref>
###xml 634 635 634 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 642 646 642 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Lobenhofer1">[30]</xref>
###xml 648 652 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Stender1">[31]</xref>
###xml 718 724 718 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 747 756 747 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Waf1/Cip1</sup>
###xml 877 886 877 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Waf1/Cip1</sup>
###xml 972 976 972 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall1">[13]</xref>
###xml 978 982 978 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Mukherjee1">[19]</xref>
###xml 1054 1063 1054 1063 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Waf1/Cip1</sup>
The 'cell cycle' network presented here integrates upstream cell cycle regulatory molecules with those more directly involved in DNA replication i.e. PCNA, Cdc6, and the MCMs. Recent evidence that c-Myc is associated with the pre-replication complex suggests one means by which estrogen could regulate DNA replication [28]. However, c-Myc regulates the number of replication origins rather than the rate of replication fork movement [28], while estrogen increases the rate of replication fork movement [29]. Since many of these DNA replication genes are E2F-responsive, estrogen stimulation of E2F activity as cells progress through G1 phase [30], [31] provides a likely mechanism for their activation. Interestingly, CDKN1A, the gene encoding p21Waf1/Cip1, is a prominent hub linking many of the genes within the 'cell cycle' signature, consistent with studies identifying p21Waf1/Cip1 as an important effector of c-Myc action on the cell cycle in estrogen-treated cells [13], [19]. Had this not already been known, our analysis would have suggested p21Waf1/Cip1 as a strong candidate for further investigation, highlighting the ability of these functional pathways to provide mechanistic insights and suggesting that some of the hubs in other networks merit further investigation as mediators of estrogen action.
###end p 53
###begin p 54
###xml 518 522 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Lonard1">[32]</xref>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Saceda1">[33]</xref>
Like the 'cell cycle' signature, the 'transcriptional regulation' signature contained approximately equal proportions of c-Myc-regulated genes and genes unresponsive to c-Myc activation. Prominent in the 'transcriptional regulation' network are a number of nuclear receptor coregulators (the coactivators NCOA1/SRC-1/RIP160, NCOA2/SRC-2/GRIP1, NCOA3/AIB1/SRC-3, NCOA7, ARNT, ARNT2 and the corepressor NRIP1/RP140), which play a central role in transcriptional activation by members of the nuclear receptor superfamily [32] and which were regulated in a manner consistent with the well-known ligand-activated downregulation of estrogen receptor signaling [33]. Interestingly, NCOA1, ARNT and ARNT2 and one of two probsets for NCOA3 were also significantly downregulated by c-Myc, suggesting that c-Myc-mediated repression may also contribute to this response.
###end p 54
###begin p 55
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Hamilton1">[34]</xref>
###xml 665 669 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Kirkland1">[35]</xref>
###xml 744 748 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-White1">[24]</xref>
###xml 750 754 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Oskarsson1">[36]</xref>
Estrogen regulates both RNA and protein synthesis, an important physiological response that was the focus of much early work on estrogen action [34]. However, the molecular mechanisms for estrogen effects on cell growth remain largely unexplored. We show here that almost all of the acutely estrogen-regulated genes with roles in cell growth are also c-Myc targets, and that estrogen activation of rRNA synthesis and protein synthesis depends on c-Myc. The idea that estrogen regulates cell growth via c-Myc is supported by evidence that estrogen induction of c-Myc in the rodent uterus is not prevented by progesterone, which inhibits DNA synthesis but not growth [35], and the known role of c-Myc in regulating cell growth in mammalian cells [24], [36].
###end p 55
###begin p 56
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Pratt1">[37]</xref>
###xml 271 275 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Perillo1">[38]</xref>
###xml 870 874 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Rodrik1">[39]</xref>
Like the 'cell cycle' network, the 'cell death' network contains both effectors and upstream regulators. Bcl-2 acts as a hub connecting many of the effectors, consistent with the well-documented role of Bcl-2 as a mediator of the anti-apoptotic effects of estrogen [37], [38]. The 'cell death' signature also contains components of survival signaling pathways, e.g. receptor tyrosine kinases (IGF1R and Ret) and their effectors (IRS1, Jak1, Jak2) that are increased in response to estrogen treatment. The implications of transcriptional regulation of these signaling pathways has been much less well-studied than their regulation by protein-protein interactions and phosphorylation, but a co-ordinate increase in expression is likely to result in enhanced survival signaling. Estrogen suppression of apoptosis resulting from growth factor deprivation is c-Myc dependent [39] but genes regulated by c-Myc were under-represented in the 'cell death' signature. However, our experimental model, i.e. cells cultured in the presence of serum and insulin, is rich in survival factors, and the ability of estrogen to enhance survival signaling may further oppose the ability of c-Myc to promote apoptosis in this model.
###end p 56
###begin title 57
Deregulation of estrogen action and endocrine resistance
###end title 57
###begin p 58
###xml 262 266 262 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Loi1">[10]</xref>
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Paik1">[40]</xref>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Dowsett1">[42]</xref>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Loi2">[11]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Loi1">[10]</xref>
###xml 639 645 639 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 1176 1184 <span type="species:ncbi:9606">patients</span>
An association between increased breast cancer proliferation and poor outcome in response to endocrine therapies is clearly apparent from studies measuring both individual markers of proliferation (e.g. Ki67) and gene signatures associated with reduced survival [10], [40]-[42]. The particularly poor outcome of highly proliferative ER-negative breast cancers and the association between signatures containing prominent proliferation-related components, for example the genomic grade signature [11], and poor outcome in both untreated and tamoxifen-treated ER+ve breast cancers [10], raises the question of whether increased proliferation per se is a marker of an adverse prognosis, or whether there are aspects of loss of proliferative control that affect response to individual therapies. Whether the signatures identified here are specifically predictive of response to tamoxifen or might also be associated with poor response to other therapies remains to be determined. However, in contrast with previous analyses in breast cancer, we have distinguished cell cycle/cell growth, and cell survival signatures that are independent predictors of outcome in tamoxifen-treated patients.
###end p 58
###begin p 59
###xml 176 179 176 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 301 305 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Tomlins1">[43]</xref>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Tomlins1">[43]</xref>
A recent analysis of 'molecular concepts' associated with progression of prostate cancer identified increased protein synthesis and enrichment at chromosome 8q, which includes MYC (8q24), as features distinguishing the precursor lesion prostatic intraepithelial neoplasia (PIN) from benign epithelium [43]. The proliferation signature was distinct from the protein synthesis network, and although both increased during disease progression, they did so at different stages [43], consistent with the idea that enhanced cell cycle progression and enhanced cell growth may reflect different initiating events. In our analysis c-Myc-responsive genes predominated in the 'cell growth' signature, which contains many of the most strongly c-Myc-regulated genes. The 'cell growth' signature may therefore be a surrogate measure of deregulated c-Myc expression that identifies a subset of proliferative, endocrine-resistant breast cancers with distinct biology.
###end p 59
###begin p 60
###xml 238 241 238 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 246 261 246 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CSN5/JAB1/COPS5</italic>
###xml 261 265 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Adler1">[44]</xref>
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Fan1">[45]</xref>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
The poor outcome associated with the 'cell growth' signature may reflect a specific resistance to endocrine therapies associated with deregulation of c-Myc. However, the 'wound signature', which is induced by co-ordinate amplification of MYC and CSN5/JAB1/COPS5[44], is predictive of a poor outcome in a cohort of patients with ER-positive cancers who were more commonly treated with chemotherapy than endocrine therapy [45], suggesting that deregulation of c-Myc may result in resistance to multiple therapies.
###end p 60
###begin p 61
###xml 356 363 356 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 363 379 363 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Butt3">[reviewed in 46]</xref>
###xml 504 508 504 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Jansen1">[47]</xref>
###xml 1135 1139 1135 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Wang1">[48]</xref>
The well-established role of estrogen in promoting cell survival suggests that increased apoptosis might be associated with a better clinical response to endocrine therapies. However, clinical studies addressing this question have often revealed conflicting data, perhaps because of inherent difficulties in accurately monitoring the dynamics of apoptosis in vivo[reviewed in 46]. As found by another study identifying genes differentially expressed in tamoxifen-sensitive and -insensitive breast cancer [47], the adverse outcome predicted by the 'cell death' signature was associated with both pro-apoptotic and anti-apoptotic changes in gene expression. Consequently the likely effect of the observed changes in expression within the 'cell death' signature is not clear. The dual role of a subset of genes within the signature in regulating invasion and motility provides another mechanism whereby their deregulation may impair response to endocrine therapies. For example, Bcl-2, which has functional interactions with many other genes within the signature, has been implicated in estrogen regulation of invasion downstream of RelB [48].
###end p 61
###begin p 62
###xml 239 247 <span type="species:ncbi:9606">patients</span>
In summary, the main findings of this work are the predominance of c-Myc as a target of estrogen action, its specific role as a mediator of estrogen effects on cell growth, and the ability of functionally-based gene signatures to stratify patients treated with tamoxifen into groups with differing outcome, potentially identifying distinct mechanisms of tamoxifen resistance. This provides an opportunity to identify new therapeutic options for endocrine-resistant breast cancer.
###end p 62
###begin title 63
Materials and Methods
###end title 63
###begin title 64
Plasmid construction and transfection
###end title 64
###begin p 65
###xml 97 101 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Daly1">[49]</xref>
###xml 133 137 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall1">[13]</xref>
###xml 221 225 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Mukherjee2">[50]</xref>
###xml 180 185 <span type="species:ncbi:10090">mouse</span>
The plasmids pDeltaMT and pDeltaMT-Myc, which contain a metal-inducible metallothionein promoter [49] have been previously described [13]. pDeltaMT-c-Zip was constructed using the mouse c-Zip cDNA subcloned from KS c-Zip [50]. MCF-7 cells were transfected with either pDeltaMT, pDeltaMT-c-Myc or pDeltaMT-c-Zip together with a plasmid containing a selectable marker (puromycin). Multiple individual puromycin-resistant colonies (10-20 for each construct) were isolated, expanded and characterised.
###end p 65
###begin title 66
Cell culture, DNA flow cytometry and measurement of protein synthesis
###end title 66
###begin p 67
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Sutherland1">[51]</xref>
###xml 284 288 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall2">[52]</xref>
MCF-7 cells were maintained as previously described [51]. Stock solutions of the pure antiestrogen ICI 182780 {7alpha-[9-(4,4,5,5-pentafluoropentyl-sulfinyl)nonyl]estra-1,3,5(10)-triene-3,17beta-diol} and the steroid estradiol (17beta-estradiol) were prepared as described previously [52]. Stocks of Nocodazole {methyl-[5-(2-thienyl-carbonyl)-1H-benzimidazol-2-yl] carbamate} were prepared in DMSO and used at a final concentration of 50 ng/ml.
###end p 67
###begin p 68
###xml 168 169 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 194 195 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 221 225 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall1">[13]</xref>
###xml 286 290 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall1">[13]</xref>
###xml 360 362 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 412 416 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Poortinga1">[53]</xref>
Exponentially proliferating cells were growth arrested by pretreatment for 48 h with the steroidal antiestrogen ICI 182780 (10 nM) and then treated with either 100 nM E2 or 65 microM Zn (as ZnSO4) as previously described [13]. DNA analysis by flow cytometry was as previously described [13]. To measure protein synthesis MCF-7 cells were labeled with 45 muCi [35S]-methionine for 20 mins as previously described [53].
###end p 68
###begin title 69
Myc siRNA
###end title 69
###begin p 70
###xml 536 537 536 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
siRNAs (siMyc-17 (D-003282-17-0050), non-targeting control 2 (D-001210-02-20) and RISC-Free siRNA (D-001220-01-20)) were purchased from Dharmacon (Lafayette, Colorado, USA) and transfected at 50 or 100 nM using Lipofectamine 2000 (Invitrogen). Transfection with fluorescinated siRNAs showed that >98% of target cells were transfected. The siRNA/transfection mix was removed 24 h after transfection and replaced with fresh RPMI medium containing ICI 182780 (10 nM). After a further 48 h the cells were treated with vehicle (ethanol) or E2 (17-beta estradiol, 100 nM).
###end p 70
###begin title 71
Western blot analysis
###end title 71
###begin p 72
###xml 69 73 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Prall2">[52]</xref>
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
###xml 519 525 <span type="species:ncbi:9986">rabbit</span>
Cell lysates were prepared and immunoblotted as previously described [52]. The following primary mouse monoclonal antibodies were used: cyclin D1 (DSC-6, Novocastra, Laboratories Ltd, Newcastle-upon-Tyne, UK), beta-actin (AC-15, Sigma, St Louis, MO, USA), p21 (610233; BD Transduction Laboratories, Lexington, KY, USA), p27 (610241, BD Transduction Laboratories, Lexington, KY, USA), pRB (554136, BD Pharmigen, San Diego, CA, USA), c-Myc (9E10, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA). The following primary rabbit polyclonal antibodies were used: cyclin A (C-19), and c-Myc (C-19) (Santa Cruz Biotechnology).
###end p 72
###begin title 73
Quantitative Real-Time PCR
###end title 73
###begin p 74
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RPLPO</italic>
###xml 286 289 <span type="species:ncbi:9606">Man</span>
Total RNA was isolated using the RNAeasy kit (Qiagen) from E2 or vehicle and Zn-treated cells and reverse-transcribed using the Reverse Transcription System (Promega, NSW, Australia). Real-time PCR was performed using an ABI Prism 7900HT Sequence Detection System using inventoried Taq-Man probes (Applied Biosystems, Foster City, CA, USA). GAPDH and RPLPO were used as internal controls.
###end p 74
###begin title 75
Transcript profiling and microarray data analysis
###end title 75
###begin p 76
###xml 96 97 96 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 323 324 311 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 459 464 <span type="species:ncbi:9606">Human</span>
RNA was collected in three independent experiments, each including parental cells treated with E2 or ethanol, zinc-treated pDeltaMT-c-Myc cells, zinc-treated pDeltaMT-c-Zip cells and zinc-treated empty vector (pDeltaMT) cells. Cells were arrested for 48 h with 10 nM ICI 182780 and then treated for 6 h with either 100 nM E2 or ethanol vehicle, or 75 microM zinc for the stably transfected cell lines. Target probes were prepared and hybridised to Affymetrix Human Genome U133 Plus 2.0 oligonucleotide microarrays (Millennium Science, Box Hill, Vic, Australia) according to the manufacturer's instructions. The microarray data are available through the Gene Expression Omnibus (GEO) database (accession number GSE11791).
###end p 76
###begin p 77
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">affy</italic>
###xml 186 196 186 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">simpleaffy</italic>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Gentleman1">[54]</xref>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">affy</italic>
Quality of the arrays was assessed using histograms of probe intensity, RNA degradation plots and Affymetrix-style quality control measures generated using functions within the affy and simpleaffy package of Bioconductor [54]. The arrays showed similar 'gamma' shaped distributions of probeset intensities, and had scaling factors of 0.995-2.048 units, confirming their high quality and suitability for batch normalization. Normalization of the arrays was performed using the RMA algorithm, as implemented in the affy package of Bioconductor and using the default options of RMA (with background correction, quantile normalization, and log transformation).
###end p 77
###begin p 78
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">limma</italic>
###xml 155 159 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Smyth1">[55]</xref>
###xml 343 347 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Benjamini1">[56]</xref>
###xml 358 366 358 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">multtest</italic>
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Tang1">[16]</xref>
###xml 559 563 559 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Zeller1">[17]</xref>
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Andersen1">[22]</xref>
###xml 661 665 661 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Draghici1">[20]</xref>
###xml 748 752 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Rhodes1">[21]</xref>
###xml 876 877 874 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 716 723 <span type="species:ncbi:28980">Redwood</span>
After normalisation probesets with intensity >100 in any of the experimental conditions were analysed using Bayesian linear modelling in the limma package [55], with replicate and treatment as fixed effects. Penalized t-statistics from these comparisons were generated by Benjamini and Yekutieli adjustment for multiple-hypothesis comparisons [56] using the multtest package and probes displaying significant differential expression (adjusted p<0.01) were identified and compared with databases of estrogen-responsive genes ((ERGDB, , [16]), c-Myc targets (, [17]), and nucleolar proteins (, [22] current in November 2005. Pathway analysis used Onto-Express (, [20]), Ingenuity Pathways Analysis (Ingenuity Systems, Redwood City, CA, ), and HiMAP ([21]. Gene ontology and functional annotation is presented for only those categories containing >/=3 genes and with an adjusted P value <0.01.
###end p 78
###begin title 79
Clinical microarray data
###end title 79
###begin p 80
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Loi2">[11]</xref>
###xml 534 542 <span type="species:ncbi:9606">patients</span>
The clinical dataset used for analyzing the relationship between the functional gene signatures and response to endocrine therapy consisted of 246 primary breast cancer samples. The demographics and methods have been previously described [11] and the raw data are available at the GEO database (accession number GSE6532). All samples were required to be estrogen and/or progesterone receptor positive by ligand-binding assay and had received tamoxifen monotherapy only in the adjuvant setting. The cut-off value for classification of patients as ER-positive or -negative was 10 fmol per mg protein. The primary endpoint used for generating the classifiers was the first distant metastatic event as survival can be confounded by local recurrence and treatments given at relapse.
###end p 80
###begin p 81
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002987-Bair1">[25]</xref>
###xml 540 542 540 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 612 613 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1084 1085 1084 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 1675 1682 <span type="species:ncbi:9606">patient</span>
Data analyses were performed using version 3.5 of BRB ArrayTools (). The survival analyses were performed using the 'survival risk prediction tool' where the survival risk groups are constructed using a supervised principal component method [25]. All genes from each of the functional networks that were present on the U133A Affymetrix microarrays used for analysis of gene expression in tamoxifen-treated patients were entered to generate the classifier. Two principal components, 10-fold cross-validation and a binary cut-off using the 50th percentile were used to generate two prognostic groups. The log-rank P value for the Kaplan-Meier curve was generated after 500 permutations. To determine the predictive accuracy of each of the functional gene signatures compared with the clinical prognostic variables alone, two models were created for each signature-one with clinical covariates only and one with the clinical covariates and the gene signature. The cross-validated Kaplan-Meier curves and log-rank statistics for these models were generated after 500 permutations and the P value measures whether the expression data significantly adds to predictive accuracy compared with the clinical factors alone. This approach is preferable to a multivariate model which only compares prognostic effects and can be unstable due to multi-colinearity between variables in the model and random fluctuations in the data. Multivariate Cox regression analyses were performed using SPSS statistical software package (SPSS Inc. Chicago, IL) version 13.0. Each gene signature and tumor grade (1 vs. 2 vs. 3) were treated as continuous variables, while tumor size (</=2 cm vs. >2 cm), patient age (</=50 vs. >50 yrs) and nodal status (positive vs. negative) were treated as binary variables.
###end p 81
###begin title 82
Supporting Information
###end title 82
###begin p 83
Estrogen-regulated genes
###end p 83
###begin p 84
(0.46 MB XLS)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
Estrogen-regulated gene signatures.
###end p 86
###begin p 87
(0.13 MB XLS)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin p 89
Ingenuity annotation of gene signatures
###end p 89
###begin p 90
(0.17 MB XLS)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
We thank Dr Sophie Doisneau-Sixou and Christine Lee for assistance with some experiments and Drs Andrew Biankin, Jason Carroll, Roger Daly and Ross Hannan for helpful discussions and comments on the manuscript.
###end p 92
###begin title 93
References
###end title 93
###begin article-title 94
###xml 45 50 <span type="species:ncbi:9606">women</span>
Adjuvant endocrine therapy for premenopausal women with early breast cancer.
###end article-title 94
###begin article-title 95
###xml 57 62 <span type="species:ncbi:9606">women</span>
Advances in adjuvant hormonal therapy for postmenopausal women.
###end article-title 95
###begin article-title 96
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
###end article-title 96
###begin article-title 97
Overview of the main outcomes in breast-cancer prevention trials.
###end article-title 97
###begin article-title 98
Chemoprevention of breast cancer with selective oestrogen-receptor modulators.
###end article-title 98
###begin article-title 99
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
###end article-title 99
###begin article-title 100
Endocrine-responsive breast cancer and strategies for combating resistance.
###end article-title 100
###begin article-title 101
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
###end article-title 101
###begin article-title 102
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
###end article-title 102
###begin article-title 103
The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response.
###end article-title 103
###begin article-title 104
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
###end article-title 104
###begin article-title 105
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.
###end article-title 105
###begin article-title 106
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.
###end article-title 106
###begin article-title 107
Repeated observation of breast tumor subtypes in independent gene expression data sets.
###end article-title 107
###begin article-title 108
###xml 86 91 <span type="species:ncbi:9606">human</span>
Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle.
###end article-title 108
###begin article-title 109
ERGDB: Estrogen Responsive Genes Database.
###end article-title 109
###begin article-title 110
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.
###end article-title 110
###begin article-title 111
###xml 103 110 <span type="species:ncbi:9606">patient</span>
The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.
###end article-title 111
###begin article-title 112
###xml 98 103 <span type="species:ncbi:9606">human</span>
c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells.
###end article-title 112
###begin article-title 113
Global functional profiling of gene expression.
###end article-title 113
###begin article-title 114
###xml 27 32 <span type="species:ncbi:9606">human</span>
Probabilistic model of the human protein-protein interaction network.
###end article-title 114
###begin article-title 115
Nucleolar proteome dynamics.
###end article-title 115
###begin article-title 116
###xml 16 21 <span type="species:ncbi:9606">human</span>
A wiring of the human nucleolus.
###end article-title 116
###begin article-title 117
RNA polymerases I and III, growth control and cancer.
###end article-title 117
###begin article-title 118
###xml 35 42 <span type="species:ncbi:9606">patient</span>
Semi-supervised methods to predict patient survival from gene expression data.
###end article-title 118
###begin article-title 119
Transcriptional regulation and transformation by Myc proteins.
###end article-title 119
###begin article-title 120
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters.
###end article-title 120
###begin article-title 121
Non-transcriptional control of DNA replication by c-Myc.
###end article-title 121
###begin article-title 122
DNA replication and accelerated chain growth in oestrogen-stimulated uterine cells.
###end article-title 122
###begin article-title 123
Regulation of DNA replication fork genes by 17beta-estradiol.
###end article-title 123
###begin article-title 124
###xml 36 41 <span type="species:ncbi:9606">human</span>
Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation.
###end article-title 124
###begin article-title 125
###xml 34 39 <span type="species:ncbi:9606">human</span>
Nuclear receptor coregulators and human disease.
###end article-title 125
###begin article-title 126
Regulation of the estrogen receptor in MCF-7 cells by estradiol.
###end article-title 126
###begin article-title 127
Control by estrogen of genetic transcription and translation. Binding to chromatin and stimulation of nucleolar RNA synthesis are primary events in the early estrogen action.
###end article-title 127
###begin article-title 128
Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus.
###end article-title 128
###begin article-title 129
The Myc trilogy: lord of RNA polymerases.
###end article-title 129
###begin article-title 130
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 69 78 <span type="species:ncbi:10090">nude mice</span>
Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2.
###end article-title 130
###begin article-title 131
17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence.
###end article-title 131
###begin article-title 132
Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.
###end article-title 132
###begin article-title 133
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
###end article-title 133
###begin article-title 134
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
###end article-title 134
###begin article-title 135
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
###end article-title 135
###begin article-title 136
Integrative molecular concept modeling of prostate cancer progression.
###end article-title 136
###begin article-title 137
Genetic regulators of large-scale transcriptional signatures in cancer.
###end article-title 137
###begin article-title 138
Concordance among gene-expression-based predictors for breast cancer.
###end article-title 138
###begin article-title 139
Does estrogen-mediated survival signalling play a role in endocrine responsiveness?
###end article-title 139
###begin article-title 140
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.
###end article-title 140
###begin article-title 141
Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.
###end article-title 141
###begin article-title 142
###xml 140 145 <span type="species:ncbi:9606">human</span>
Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells.
###end article-title 142
###begin article-title 143
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
Myc-family proteins function through a common pathway to transform normal cells in culture: cross-reference by Max and trans-acting dominant negative mutants.
###end article-title 143
###begin article-title 144
###xml 37 42 <span type="species:ncbi:9606">human</span>
Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.
###end article-title 144
###begin article-title 145
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
###end article-title 145
###begin article-title 146
MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation.
###end article-title 146
###begin article-title 147
Bioconductor: open software development for computational biology and bioinformatics.
###end article-title 147
###begin article-title 148
Limma: linear models for microarray data.
###end article-title 148
###begin article-title 149
The control of the false discovery rate in multiple testing under dependency.
###end article-title 149
###begin p 150
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Provisional US patent filed by the Garvan Institute of Medical Research: Prognosis and therapeutic responsiveness of breast cancer.
###end p 150
###begin p 151
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This research was supported by the Association for International Cancer Research, the National Health and Medical Research Council of Australia, the Cancer Institute NSW, the Australian Cancer Research Foundation (ACRF Unit for the Molecular Genetics of Cancer), Cure Cancer Australia, the Petre Foundation and the RT Hall Trust. EAM and AJB are Cancer Institute NSW Fellows. SL is a National Breast Cancer Foundation Scholar. LRA and CEC are Cancer Institute NSW Scholars. These funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
###end p 151

